Natera, Inc. (NASDAQ:NTRA – Get Free Report) CFO Michael Brophy sold 1,198 shares of Natera stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $426.34, for a total value of $510,755.32. Following the transaction, the chief financial officer directly owned 49,658 shares of the company’s stock, valued at approximately $21,171,191.72. The trade was a 2.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Michael Burkes Brophy also recently made the following trade(s):
- On Tuesday, October 27th, Michael Brophy sold 781 shares of Natera stock. The stock was sold at an average price of $406.00, for a total transaction of $317,086.00.
- On Tuesday, August 4th, Michael Brophy sold 478 shares of Natera stock. The stock was sold at an average price of $274.22, for a total transaction of $131,077.16.
- On Monday, August 3rd, Michael Brophy sold 317 shares of Natera stock. The shares were sold at an average price of $267.99, for a total transaction of $84,952.83.
Natera Trading Up 2.7%
NTRA stock traded up $11.58 during trading on Thursday, hitting $436.00. 1,325,469 shares of the stock traded hands, compared to its average volume of 1,585,948. Natera, Inc. has a one year low of $181.00 and a one year high of $437.41. The company has a 50 day simple moving average of $375.27 and a 200 day simple moving average of $265.54.
Natera (NASDAQ:NTRA – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. The firm had revenue of $752.75 million for the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.74) earnings per share. Research analysts forecast that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.
Institutional Trading of Natera
A number of large investors have recently bought and sold shares of NTRA. BlackRock Inc. bought a new position in shares of Natera during the 2nd quarter worth approximately $2,962,770,000. Bank of America Corp DE acquired a new stake in Natera during the 2nd quarter valued at $199,960,000. Legal & General Group Plc bought a new position in Natera during the second quarter worth $150,143,000. Bank of New York Mellon Corp bought a new position in Natera during the second quarter worth $149,278,000. Finally, Avala Global LP acquired a new position in shares of Natera in the second quarter valued at $124,867,000. 99.90% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research note on Thursday, October 15th. Canaccord Genuity Group upped their price objective on Natera from $375.00 to $500.00 and gave the stock a “buy” rating in a report on Monday, October 19th. Morgan Stanley increased their price objective on Natera from $355.00 to $435.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Zacks Research cut Natera from a “hold” rating to a “strong sell” rating in a research note on Friday, October 16th. Finally, Royal Bank Of Canada boosted their target price on Natera from $350.00 to $460.00 and gave the stock an “outperform” rating in a research report on Friday, September 25th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $394.31.
Get Our Latest Research Report on Natera
Key Stories Impacting Natera
Here are the key news stories impacting Natera this week:
- Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
- Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
- Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
- Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
- Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
- Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
- Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale
About Natera
Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.
In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.
Featured Stories
- Five stocks we like better than Natera
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
